{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["durvalumab","tremelimumab","radiotherapy"]],"indication":"localized muscle-invasive bladder cancer","name":"IMMUNOPRESERVE","nct_id":"NCT03702179","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=immunopreserve-nct03702179. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"IMMUNOPRESERVE","arms":[{"description":"The treatment consisted of initial TUR of the tumor, with multiple random biopsies of normal-appearing bladder urothelium, followed by durvalumab 1500 mg i.v. plus tremelimumab 75 mg i.v., every 4 weeks for a total of 3 doses.\n\nTwo weeks after the initiation of immunotherapy, normofractionated external-beam radiotherapy with high-energy photons will be started. Radiotherapy will be administered concurrently with immunotherapy at doses of 46 Gy to the minor pelvis and 64-66 Gy to the bladder.","label":"Durvalumab + Tremelimumab","type":"EXPERIMENTAL"}],"collaborators":["AstraZeneca","MFAR"],"completion_date":{"date":"2022-08-16","type":"ACTUAL"},"conditions":["Invasive Bladder Cancer"],"enrollment":{"count":32,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Durvalumab","otherNames":["MEDI4736"],"type":"DRUG"},{"name":"Tremelimumab","otherNames":[],"type":"DRUG"},{"name":"Radiotherapy","otherNames":[],"type":"RADIATION"}],"last_update":"2024-12-05","lead_sponsor":"Spanish Oncology Genito-Urinary Group","official_title":"Phase II Trial of Durvalumab (Medi4736) Plus Tremelimumab With Concurrent Radiotherapy in Patients With Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2020-09-29","type":"ACTUAL"},"primary_outcomes":[{"measure":"Proportion of Patients With Pathological Response","timeFrame":"12 weeks"}],"references":[],"start_date":{"date":"2018-11-19","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach","url":"https://clinicaltrials.gov/study/NCT03702179"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/immunopreserve-nct03702179"}